p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia-Reference-Cited by-同舟云学术

p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia

Published:2011-06-24 Issue:11 Volume:25 Page:1739-1750
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Ng K P,Ebrahem Q,Negrotto S,Mahfouz R Z,Link K A,Hu Z,Gu X,Advani A,Kalaycio M,Sobecks R,Sekeres M,Copelan E,Radivoyevitch T,Maciejewski J,Mulloy J C,Saunthararajah Y

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2011159.pdf

Reference70 articles.

1. Vazquez A, Bond EE, Levine AJ, Bond GL . The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008; 7: 979–987.

2. Suarez L, Vidriales MB, Garcia-Larana J, Sanz G, Moreno MJ, Lopez A et al. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes. Clin Cancer Res 2004; 10: 7599–7606.

3. Yin B, Kogan SC, Dickins RA, Lowe SW, Largaespada DA . Trp53 loss during in vitro selection contributes to acquired Ara-C resistance in acute myeloid leukemia. Exp Hematol 2006; 34: 631–641.

4. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148–3157.

5. Toledo F, Wahl GM . Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006; 6: 909–923.

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ven the dose matters: Venetoclax dosing in the frontline treatment of AML;Blood Reviews;2024-08

2. Targeting BIRC5 as a therapeutic approach to overcome ASXL1-associated decitabine resistance;Cancer Letters;2024-07

3. Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules;Cancer Letters;2024-06

4. Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy;Cell Reports;2023-08

5. A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML;Clinical Cancer Research;2023-06-21